December 2014
Volume 14, Issue 15
OSA Fall Vision Meeting Abstract  |   December 2014
Stem cell strategies for retinal disease
Author Affiliations
  • Dennis Clegg
    University of California, Santa Barbara
Journal of Vision December 2014, Vol.14, 3. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dennis Clegg; Stem cell strategies for retinal disease. Journal of Vision 2014;14(15):3.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Age-related macular degeneration (AMD) is a leading cause of blindness, and treatments are limited for the non-exudative form. As AMD progresses, the retinal pigmented epithelium (RPE) in the macula lose function or die, resulting in photoreceptor loss. An exciting new direction is to use RPE derived from human embryonic stem cells (hESC) to replace RPE and preserve photoreceptors. One clinical trial that employs a bolus injection of hESC-RPE cells is already underway. A more sophisticated approach is to implant differentiated, polarized monolayers of hESC-RPE on a scaffold, whereby cells are provided with a supportive substrate. We will present recent using this strategy for the treatment of dry AMD. Strategies that combine scaffolds with ocular cells derived from pluripotent stem cells are likely to have broad application for a variety of ocular diseases and injuries.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.